David Pook

@DrMHofman @CraigUnderhill @ANZUPtrials @ciaraconduit @Prof_IanD @JeffreyCGoh1 @HowardGurney @doccharris @DrL_Krieger @Drdhadams @feliciaTSR @anthonyjoshua @LizHovey @DrCraigGedye @X @BJUIjournal I think the PBS should be funding de-escalation studies - we can all think of examples where it could save a lot of money

@CraigUnderhill @ANZUPtrials @ciaraconduit @Prof_IanD @JeffreyCGoh1 @HowardGurney @doccharris @docpook @DrL_Krieger @Drdhadams @feliciaTSR @anthonyjoshua @LizHovey @DrCraigGedye @X @BJUIjournal We should have a MRFF to fund large scale trials that aim to 1/) de escalate an expensive therapy, or 2) prove than old fashioned "standard of care" doesn't actually work.

Thanks @BJUIjournal for publishing effectively a negative study : A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma - Conduit - 2024 - BJU International - Wiley Online Library bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj… #oncology

Great to see @ANZUPtrials #UNICAB Study poster @ASCO #GU24 presented by @docpook. Well done to entire team for their ongoing hard work #kidneycancer #improvingoutcomes #BaCT @PeterMacCC @IpsenGroup @CancerAustralia @DrCraigGedye @Prof_IanD

KN-564 shows significant improvement in overall survival in RCC with 12m of adjuvant pembro with HR 0.62. Meanwhile the Nivo arm of CM-914 is negative. Unsure if this is due to differences in drug activity or just duration of treatment. #GU24

Delving into the ENZAMET trial: Radiographic progression in mHSPC may occur without PSA elevation, challenging conventional monitoring methods. The study underscores the complexity of disease progression. #ProstateCancer @Prof_IanD @ChrisSweens1 @ASCO #GU24 @OncoAlert @urotoday @oncodaily @DrChoueiri @yekeduz_emre @sophia_kamran @BraunMDPhD @AmandaNizamMD @TiansterZhang @RCCadvocate @ShuchiGulati @RuchikaTalwarMD @DrKarineTawagi @neerajaiims @montypal @crisbergerot @DrRanaMcKay @Tilki_De @CParkMD @cdanicas @FabioSchutz78 @PGrivasMDPhD

Great @ANZUPtrials poster @ASCO #GU24 Baseline disease characteristics of participants enrolled on #ENZARAD & #DASLHiCaP Congrats @niazi_Dr7 @ChrisSweens1 @DrPaulNguyen & Scott Williams @TrialsCentre @ThePCCTC @cancertrials_ie @CDNCancerTrials @MSKCancerCenter @AstellasUS @Bayer

CONTACT-02 Study showed improvement in rPFS in CRPC patients with soft tissue disease from 4.2m to 6.3m with Cabo/Atezo vs ARSI switch. Lots of questions about the ethics of randomising a patient with liver mets to ARSI switch. I would not be comfortable doing this. #GU24

BrCAAway study reports 39m rPFS with Abi+Olap in mCRPC with HRD, 8.4m for Abi and 14m for Olap. Possible synergy but less than 1/3 of monotherapy pts crossed over. 50% of pts screened for HRD were +ve which is far higher than we see in clinic. #GU24

@EdmondMKwan @ConquerCancerFd @VanProstateCtr @ResearchWyatt @BCCancer @MurthaAj @PCF_Science Awesome Ed see you there!

Grateful for @ConquerCancerFd Merit Award recognizing work at @VanProstateCtr @ResearchWyatt and @BCCancer, alongside talented @MurthaAj. Work supported by @PCF_Science. Excited to catch up with friends next wk at 20th ASCO #GU24. Please drop by Board J12 (Abs 204) to say 👋!

Very sad what we’re seeing around the World #endhate

JUST IN: some news in metastatic bladder cancer combinations via ⁦@Reuters⁩ reut.rs/46Gga8h reut.rs/46Gga8h

Gem/cis & nivolumab achieves significant PFS & OS in 1st line UC . Maintenance avelumab = 25% ⬆️ in OS, but not all pts get there. Better disease control during the chemo phase and competitive OS HR will be attractive to patients. news.bms.com/news/corporate…

Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23 full text: authors.elsevier.com/a/1hP1c5EIIgLp… Thanks to all who change rareRCC pts Tx!

Liz Liow presenting KRAB data (Australian real world kidney cancer data) @ANZUPtrials #ANZUP23 at best of the best oral abstract session @WEHI_research @DrDanielHeng

@DrCraigGedye explaining adaptive hormone therapy in prostate cancer on #EnzAdapt trial - tx is paused following a PSA response and then restarted on PD. Advantages are: 👉 patient gets a break from therapy 👉 may take longer for the cancer to develop resistance #ANZUP23

Mitch Lawrence explaining how high dose testosterone can be used to treat prostate cancer and how his team are investigating this in PDX models #ANZUP23

.@DrDarrenFeldman on Challenges & Pitfalls in #GCT Management | #ANZUP23 #testiscancer

Laura Porter discussing tumour microenvironment manipulation with carboplatin to improve uptake of Lewis Y targeted CAR T cells into prostate tumours. Keeping the dream of effective immunotherapy in prostate cancer alive. #ANZUP23

#ANZUP23 ASM is happening tomorrow! This is your final opportunity to register for the premier GU cancer meeting in the region. Secure your spot now at anzup.org.au/registration-2/. We look forward to seeing you at Melbourne Convention Centre.

New to the #ANZUP23 ASM, The Perfect Pitch workshop is chaired by @_ShankarSiva and @ciaraconduit. It is designed to discuss how to pitch an idea and how to bring new concepts forward for idea development, which could potentially move on to a fully fledged clinical trial.